| Autor: |
Marin, Chelsea, Weiss, Anna, Gooch, Jessica C. |
| Zdroj: |
Current Breast Cancer Reports; Mar2024, Vol. 16 Issue 1, p35-44, 10p |
| Abstrakt: |
Purpose of Review: To explore the landmark clinical trials which shaped contemporary chemoprevention practice, discuss trends in chemoprevention uptake, and highlight the obstacles faced along the way. Recent Findings: Poor chemoprevention uptake has been attributed to numerous factors, most notably fear of side effects and lack of physician recommendation. A lower dose of tamoxifen taken for a shorter period has been shown to be an effective alternative and harbors fewer side effects than the standard regimen for chemoprevention. Summary: Despite new regimens with more favorable side effect profiles and shorter treatment courses, chemoprevention uptake remains low. Education and decision-support interventions have not proven successful in addressing low uptake. In addition to ongoing trials aimed at maintaining the benefits of therapy while reducing adverse effects, a culture change among providers is needed to destigmatize these risk-reducing medications, with focus on referring appropriate women to specialized breast health centers. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink